Category: Thoratec Corp.Syndicate content

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves

October 7, 2014 by Brad Perriello

Allergan CEO David Pyott steps down from the board at Edwards Lifesciences to devote more time to his chief executive duties.

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec ousts Burbach, brings Grossman back

September 22, 2014 by Brad Perriello

Thoratec ousts CEO Gary Burbach and replaces him with predecessor Keith Grossman.

Thoratec's new study, $30M buyback can't stave off Wall Street exodus after dismal Q2

August 7, 2014 by Arezu Sarvestani

Thoratec's stock drops more than 26% in after-hours trading after the company lowers its full-year guidance on a dreary 2nd quarter.

New study, $30M buyback can't save Thoratec from Wall Street exodus after dismal Q2

Circulatory devices maker Thoratec (NSDQ:THOR) took a major hit yesterday as a bleak 2nd-quarter reports and a lowered outlook on the year sent its stock into a nosedive.

Covidien names Bill Burke as CFO to lead Medtronic merger | The week in medtech M&A

July 9, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Covidien taps integration chief to navigate Medtronic merger; Zimmer, Biomet appoint integration team; Thoratec inks $75M deal for Apica Cardiovascular; FTC wants more from Zimmer, Biomet on merger; Johnson & Johnson closes Ortho-Clinical Diagnostics sale

Covidien taps integration chief to navigate Medtronic merger

July 3, 2014 by Arezu Sarvestani

Covidien taps integration chief to navigate Medtronic merger

Thoratec inks $75M deal for Apica Cardiovascular

July 3, 2014 by Brad Perriello

Thoratec pays $35 million up front and puts another $40 million up in milestone payments for Apica Cardiovascular and its transapical access technology.

Thoratec inks $75M deal for Apica Cardiovascular

Thoratec (NSDQ:THOR) said it paid $35 million up front and agreed to another $40 million in potential milestone payments for Apica Cardiovascular and its transapical access technology.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec launches HeartMate III trial

June 27, 2014 by Brad Perriello

Thoratec says it's launched a clinical trial for its HeartMate III implantable heart pump it plans to useto back a bid for CE Mark approval in the European Union.

Thoratec launches HeartMate III trial

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp